Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II

Official Title

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II: A Phase II Randomized Controlled Trial


Adjuvant radiation therapy (RT) plays an important role in reducing the risks of local recurrence after surgery in uterine cancers. Standard adjuvant pelvic radiation treatment targets the pelvic lymph nodes, the post-operative bed, and the upper vagina and is typically treated with intensity modulated radiation therapy (IMRT) which has been shown to improve patient reported gastrointestinal (GI) and genitourinary (GU) toxicities. Although pelvic radiation has been shown to be effective at decreasing locoregional recurrences, patient quality of life and experience can be significantly impacted as pelvic RT comprises of daily radiation for 25 daily treatments, which can be a substantial burden on patients with this disease. Hypofractionated radiation therapy to a dose of 30 Gy in 5 fractions (6 Gy given every other day) for adjuvant radiation treatment in uterine cancer is hypothesized to result in similar rates of acute gastrointestinal toxicities as conventional fractionated radiation.

Trial Description

Primary Outcome:

  • Acute bowel toxicity
Secondary Outcome:
  • Acute bowel toxicities
  • Acute urinary toxicities through CTCAE
  • Acute urinary toxicities through EPIC
  • Local- regional failure
  • Disease-free survival
  • Quality of life using EORTC QLQ-30 and endometrial module (EN-24)
  • Correlation of GU toxicity, EORTC, and EPIC

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society